Never forgotten, Jack, USA
Never forgotten, Maddox, USA
Papers & Resources
Leigh syndrome chapter in Handbook of Neurology 2023
This chapter summarises the current state of the art of knowledge about Leigh's disease, including the following: historical and epidemiological perspectives, diagnostic criteria, clinical features, neuropathology, genetics, and approaches to diagnosis and treatment.Learn More
MitoCarta3.0 is an inventory of 1136 human and 1140 mouse genes encoding proteins with strong support of mitochondrial localization, now with sub-mitochondrial compartment and pathway annotations.Learn More
The Leigh Map is a gene-to-phenotype interaction network which can be used as a diagnostic resource for Leigh syndrome, in combination with genetic sequencing. The user interface of Leigh Map is similar to Google Maps, whereby the user can zoom in to view increasingly detailed components and query elements of the map.Learn More
Safety of Drug Use in Patients with a Primary Mitochondrial Disease
In this paper a panel of 16 experts in mitochondrial medicine, pharmacology, and basic science from six different countries worked together to establish a consensus on safe medication use in patients with a primary mitochondrial disease.Learn More
International Classification of Inherited Metabolic Disorders (ICIMD)
ICIMD is a hierarchical, group-based collation of all currently known inherited metabolic disorders. It aims to facilitate an improved understanding of the interconnections between conditions that share functional, clinical and diagnostic features.Learn More
Leigh syndrome global patient registry: uniting patients and researchers worldwide
This is the first publication to present results from a global patient registry for Leigh Syndrome, with details on a variety of patient-specific and caregiver outcomes reported for the first time.Learn More
Expert panel curation of 113 primary mitochondrial disease genes for the Leigh syndrome spectrum
The gene disease relationship with Leigh's disease spectrum across the nuclear and mitochondrial genomes was classified as definitive for 31/114 gene-disease relationships curated (27%); moderate for 38 (33%); limited for 43 (38%); and 2 as disputed (2%). Ninety genes were associated with autosomal recessive inheritance, 16 were maternally inherited, 5 autosomal dominant, and 3 X-linked.Learn More
Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society
The purpose of this statement is to provide consensus-based recommendations for optimal management and care for patients with primary mitochondrial disease. This statement is intended for physicians who are engaged in the diagnosis and management of these patients.Learn More
Clinical trials maybe an option for some patients. It is important to discuss the purpose, procedures, potential risks and benefits, informed consent process, and patient rights and protections. Patients should be encouraged to ask questions and informed about available support resources.Learn More
Tips for an appointment with the family
It is important to be mindful of where the patient and family are at a given time. Some families have been on a long diagnostic journey or have been a part of the medical system for a long time, while others have been generally healthy and have encountered a serious diagnosis for the first time. Knowing and keeping this in mind can really help frame the conversations with the patient and family.
If meeting a patient for the first time please find out what they already know and understand about their disease and what are their views and beliefs about it. Some potential questions to ask are:
- What have you been told so far about your diagnosis/genetic report/symptoms?
- You have probably already thought this information over. What does the information you know so far mean to you and your family?
- What do you hope to get out of this appointment or care at this hospital?
- What has been your support system or what has helped you cope so far?
- What are your general goals of care? (examples: try anything that may help, prolong life as much as possible, assure as good a quality of life as possible, enjoy time with family to the extent possible, other goals)
- How much are you looking to be informed about your disease/mutation type? (examples: as much information as possible, only what’s necessary now, other)
Be cognizant of the patient’s/family’s reaction to the information provided. Are they absorbing it? Do they appear scared or overwhelmed? Ask and adjust your approach if necessary.
Let the patient/family know what type of follow-up to expect, how to be in touch, and the anticipated response time. If the medical provider is not the one who will be responding to follow-up inquiries, it is especially important to be clear so that the patient/family has an opportunity to ask all important questions during the appointment.
It is important to clearly communicate a plan for the timing of receiving and reviewing any ordered tests or labs. It can be difficult for patients to receive results they do not understand and have to wait for clarification.
When preparing a post-visit letter, it is imperative that it only contains information that was discussed with the patient during the appointment. It can be challenging to receive a letter several weeks after the appointment with new information or recommendations that were not previously discussed.
Tips for sharing difficult news with the family
Patient families often say that the moment they got a diagnosis or other difficult news has stayed with them forever - they remember every word, every detail of that conversation. We hope these tips will help.
Download this resource
Download these resources to save, print, or share. We hope these are helpful as you are navigating Leigh’s disease together with your patients.